Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy.
Adult
Cerebrospinal Fluid
/ cytology
Female
HIV Infections
/ cerebrospinal fluid
Humans
Hydrocephalus, Normal Pressure
/ cerebrospinal fluid
Leukoencephalopathy, Progressive Multifocal
/ cerebrospinal fluid
Male
Middle Aged
Multiple Sclerosis
/ cerebrospinal fluid
Pseudotumor Cerebri
/ cerebrospinal fluid
Retrospective Studies
Cerebrospinal fluid
HIV
Lymphoma
Multiple sclerosis
Progressive multifocal leukoencephalopathy
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
27 Oct 2020
27 Oct 2020
Historique:
received:
21
07
2020
accepted:
17
10
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
17
8
2021
Statut:
epublish
Résumé
Progressive multifocal leukoencephalopathy (PML) is caused by an opportunistic infection with JC polyoma virus (JCPyV) and mainly affects immunocompromised patients. It leads to pronounced demyelination of the central nervous system (CNS) resulting in severe disability or even death. Detection of JCPyV DNA in the cerebrospinal fluid (CSF) is usually accepted as proof for the diagnosis of PML. Routine CSF parameters, like CSF cell count, protein concentration, Qalbumin, or intrathecal immunoglobulin synthesis are mostly considered normal. However, this has not been investigated systematically. We analyzed routine CSF parameters in a cohort of 108 PML patients that were treated at four different neurological centers in Germany. The patients exhibited different underlying conditions with natalizumab-treated multiple sclerosis (n = 54) and human immunodeficiency virus (HIV)-infection (n = 25) being the most frequent. The data were collected at the respective centers in accordance with local requirements and then jointly analyzed. The total PML cohort was compared with a control group of patients with normal pressure hydrocephalus (NPH) and idiopathic intracranial hypertension (IIH). Multiple sclerosis and HIV patients were additionally compared with their own non-PML control groups. The PML group showed an elevated cell count (p < 0.001) compared to the control group, however, this effect was mainly driven by HIV-PML patients. This subgroup also demonstrated a significantly higher proportion of patients with a disturbed blood-CSF-barrier function. This comprehensive, retrospective study on CSF diagnostic analysis in PML patients provides insight into the CSF of those patients. It demonstrates that CSF composition in PML patients may be specific for the underlying condition that predisposes for the development of PML and thus data have to be interpreted in this context.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive multifocal leukoencephalopathy (PML) is caused by an opportunistic infection with JC polyoma virus (JCPyV) and mainly affects immunocompromised patients. It leads to pronounced demyelination of the central nervous system (CNS) resulting in severe disability or even death. Detection of JCPyV DNA in the cerebrospinal fluid (CSF) is usually accepted as proof for the diagnosis of PML. Routine CSF parameters, like CSF cell count, protein concentration, Qalbumin, or intrathecal immunoglobulin synthesis are mostly considered normal. However, this has not been investigated systematically.
METHODS
METHODS
We analyzed routine CSF parameters in a cohort of 108 PML patients that were treated at four different neurological centers in Germany. The patients exhibited different underlying conditions with natalizumab-treated multiple sclerosis (n = 54) and human immunodeficiency virus (HIV)-infection (n = 25) being the most frequent. The data were collected at the respective centers in accordance with local requirements and then jointly analyzed. The total PML cohort was compared with a control group of patients with normal pressure hydrocephalus (NPH) and idiopathic intracranial hypertension (IIH). Multiple sclerosis and HIV patients were additionally compared with their own non-PML control groups.
RESULTS
RESULTS
The PML group showed an elevated cell count (p < 0.001) compared to the control group, however, this effect was mainly driven by HIV-PML patients. This subgroup also demonstrated a significantly higher proportion of patients with a disturbed blood-CSF-barrier function.
CONCLUSIONS
CONCLUSIONS
This comprehensive, retrospective study on CSF diagnostic analysis in PML patients provides insight into the CSF of those patients. It demonstrates that CSF composition in PML patients may be specific for the underlying condition that predisposes for the development of PML and thus data have to be interpreted in this context.
Identifiants
pubmed: 33109245
doi: 10.1186/s12987-020-00227-y
pii: 10.1186/s12987-020-00227-y
pmc: PMC7590675
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 390874280
Références
Neurology. 2017 Mar 21;88(12):1144-1152
pubmed: 28228569
Dis Markers. 2014;2014:162576
pubmed: 25374433
Mult Scler. 2014 Dec;20(14):1900-3
pubmed: 24948690
J Infect Dis. 2006 Dec 15;194(12):1686-96
pubmed: 17109340
Ann Neurol. 2009 Apr;65(4):367-77
pubmed: 19399841
Lancet Neurol. 2017 Nov;16(11):925-933
pubmed: 28969984
PLoS One. 2013 Jun 18;8(6):e66188
pubmed: 23822975
J Neurovirol. 1998 Feb;4(1):59-68
pubmed: 9531012
Scand J Infect Dis. 1994;26(5):523-33
pubmed: 7855550
N Engl J Med. 2012 May 17;366(20):1870-80
pubmed: 22591293
Neurology. 2013 Apr 9;80(15):1430-8
pubmed: 23568998
Neurology. 2019 May 7;92(19):e2232-e2239
pubmed: 30952796
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii64-5
pubmed: 19022817
BMC Infect Dis. 2005 Nov 02;5:98
pubmed: 16266436
Curr Treat Options Neurol. 2008 May;10(3):178-85
pubmed: 18579021
J Neurovirol. 2019 Apr;25(2):284-287
pubmed: 30864100
N Engl J Med. 2019 Apr 25;380(17):1597-1605
pubmed: 30969503
Neurol Neuroimmunol Neuroinflamm. 2019 Sep 25;6(6):
pubmed: 31554669
Mult Scler. 2013 Aug;19(9):1209-12
pubmed: 23093485
Lancet Neurol. 2010 Apr;9(4):425-37
pubmed: 20298966
Fluids Barriers CNS. 2019 Sep 5;16(1):28
pubmed: 31484537
Arch Neurol. 2011 Sep;68(9):1156-64
pubmed: 21555606
Brain. 1958 Mar;81(1):93-111
pubmed: 13523006
Arch Neurol. 1988 Sep;45(9):954-8
pubmed: 2970837
J Neurovirol. 2018 Feb;24(1):119-122
pubmed: 29139004
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
N Engl J Med. 2019 Apr 25;380(17):1674-1676
pubmed: 30969500
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
N Engl J Med. 2019 Jan 3;380(1):106
pubmed: 30601739